Reliability of a new recombinant immunoblot assay (RIBA HIV-1/HIV-2 SIA) as a supplemental (confirmatory) test for HIV-1 and HIV-2 infections. NLM AIDSLINE Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Reliability of a new recombinant immunoblot assay (RIBA HIV-1/HIV-2 SIA) as a supplemental (confirmatory) test for HIV-1 and HIV-2 infections.

Transfus Sci. 1997 Mar;18(1):63-9. Unique Identifier : AIDSLINE HTA/98037883
Mas A; Soriano V; Gutierrez M; Fumanal F; Alonso A; Gonzalez-Lahoz J; Service of Infectious Diseases, Instituto de Salud Carlos III,; Madrid, Spain.


Abstract: The diagnosis of HIV infection is usually determined using serological methods. Positive results in a screening test should be confirmed with more specific supplementary assays, and the Western blot (WB) is the most frequently used. However, problems of WB, particularly in regard to the significance of indeterminate results, still remain. We evaluate a new recombinant HIV-1/2 antigen-based immunoblot (RIBA) as confirmatory assay in a panel of 190 clinical samples. The RIBA was much more sensitive and specific than WB. In particular, the test allows for a significant reduction in the number of indeterminate results and for more accurate distinction between HIV-1 and/or HIV-2 infections. Thus, these results make tests such as the RIBA instead of WB particularly attractive for validating anti-HIV EIA reactivity.
Keywords: Human HIV Infections/*DIAGNOSIS HIV-1/IMMUNOLOGY/*ISOLATION & PURIF HIV-2/IMMUNOLOGY/*ISOLATION & PURIF Immunoblotting/*METHODS Recombinant Proteins/IMMUNOLOGY Sensitivity and Specificity JOURNAL ARTICLEKWDhumanhivinfections/KWDdiagnosishiv-1/immunology/KWDisolation&purifhiv-2/immunology/KWDisolation&purifimmunoblotting/KWDmethodsrecombinantproteins/immunologysensitivityandspecificityjournalarticle
980228
M9820771

Copyright © 1998 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .